147214-39-9

Basic information

• Product Name: 2-bromo-3-4-difluoropropiophenone
• Synonyms: 2-bromo-3-4-difluoropropiophenone;2-bromo-1-(3,4-difluorophenyl)propan-1-one
• CAS NO: 147214-39-9
• Molecular Formula: C8H5BrF2O
• Molecular Weight: 249.0521
• Mol File: 147214-39-9.mol

Chemical Properties

• Boiling Point: 269.3 °C at 760 mmHg
• Flash Point: 116.6 °C
• Appearance: /
• Density: 1.561 g/cm³
• CAS DataBase Reference: 2-bromo-3-4-difluoropropiophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-3-4-difluoropropiophenone(147214-39-9)
• EPA Substance Registry System: 2-bromo-3-4-difluoropropiophenone(147214-39-9)

Safety Data

• Hazardous Substances Data: 147214-39-9(Hazardous Substances Data)

Upstream product

• 23384-72-7 1-(3,4-difluorophenyl)propan-1-one 

Relevant articles and documents

Novel Imidazole Derivatives Useful for the Treatment of Arthritis

The present invention provides compounds of the formula below: where A, X and R1-R6 are as described herein, a pharmaceutical salt thereof, and a pharmaceutical composition containing this compound; methods of treating pain associated with osteoarthritis using one of the compounds or a pharmaceutically acceptable salt thereof, and processes for preparing the compounds.

MONOAM1NE REUPTAKE INHIBITORS

The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine,and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity

Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction

A series of bupropion (1a) analogues (1b-1ff) were synthesized, and their in vitro and in vivo pharmacological properties evaluated with the goal of developing a 1a analogue that had better properties for treating addictions. Their in vitro pharmacological properties were examined by [3H] dopamine ([3H]DA), [3H]serotonin ([3H]5HT), and [3H]norepinephrine ([3H]NE) uptake inhibition studies, and by binding studies at the dopamine, serotonin, and norepinephrine transporters using [125I]RTI-55 in cloned transporters. Several analogues showed increased [3H]DAuptake inhibition with reduced or little change in [3H]5HT and [3H]NE uptake inhibition relative to bupropion. Thirty-five analogues were evaluated in a 1 h locomotor activity observation test and 32 in an 8 h locomotor activity observation test and compared to the locomotor activity of cocaine. Twenty-four analogues were evaluated for generalization to cocaine drug discrimination after i.p. administration, and twelve analogues were tested in a time course cocaine discrimination study using oral administration. 2-(N-Cyclopropylamino)-3- chloropropiophenone (1x) had the most favorable in vitro efficacy and in vivo pharmacological profile for an indirect dopamine agonist pharmacotherapy for treating cocaine, methamphetamine, nicotine, and other drugs of abuse addiction. 2009 American Chemical Society.

Arylmorpholine, preparation and use

A method for the treatment of depression in a human being, the method comprising administering to the human being an antidepressant effective amount of a compound of the following formula STR1 or a pharmaceutically acceptable salt thereof, wherein R and R